Argenx’s I.V. Vyvgart May See Continued Role In ITP, Despite SubQ Version Coming

The company presented Phase III data for the I.V. formulation at ASH showing a high response rate in pretreated patients, a difficult-to-treat population. It also has a subcutaneous version in Phase III.